Podcasts about glycobiology

In this episode of The Chain, host Brandon DeKosky, associate professor, speaks with MIT colleague Jessica Stark, Underwood-Prescott career development professor, about glycans and why they are important in cancer research. Stark discusses how she became interested in immunology, what her PhD and post-doctoral training was like, her thoughts on singlets operating as part of a network of checkpoint molecules, and what's currently going on in glycobiology. She also talks about her keynote presentation at PEGS 2025 and what her new lab is working on. LINKS: MIT Department of Chemical Engineering MIT Department of Biological Engineering MIT 

Joining Jill and Doron on the 34th episode of the podcast, the sixteenth of our second season, to tell us his story is esteemed British scientist Professor Raymond Dwek, who attended Carmel College from 1949 to ‘60, accompanied by his older brother Joe.  Both brothers would go on to become governors of Carmel. Raymond studied Chemistry at Manchester University and completed his DPhil at Oxford University.  During this time, both Raymond and his wife Sandra also taught at Carmel.  He became Professor of Glycobiology, a field he was instrumental in creating, in the Department of Biochemistry at Oxford, which he headed for several years.  He is an emeritus fellow of Exeter College at Oxford and emeritus director of the Oxford Glycobiology Institute, which he founded.  The institute gave rise to a company that became publicly listed and developed a drug - eventually approved worldwide - for Gaucher disease, a rare, genetic metabolic disorder with a much enhanced incidence among Ashkenazi Jews.  A second company that arose from the institute was taken over by United Therapeutics, a $15 billion NASDAQ-listed US biotech company, of which Raymond is a Director.  He has authored several scientific volumes and over 600 published papers, has formally advised scientific institutions in Israel, the United States and China, was appointed Commander of the Order of the British Empire for services to scientific collaboration between the United Kingdom and Israel, and was elected a Fellow of the Royal Society.  He and Sandra live in Oxford, and have four children, including a daughter, Deborah, who also attended Carmel. Hear Raymond talk about the Dwek dynasty, an unexpected guest at a midnight feast, the best teacher he ever knew, his brother Joe's ‘special diet', building Ben Gurion University from a camel market, his CBE award by Princess Anne, and the secret to a long and happy marriage. Thank you, Professor Raymond Dwek, for turning us again to Carmel days!   Dedication: at Raymond's request, this episode is dedicated to his daughter Deborah, his brother Joe, and Joe's son Jonathan, all of whom went to Carmel, along with all the other members of the Dwek family that did so too.    Personal mentions in this episode: Rabbi Dr. Kopul Rosen (Headmaster) Bella Rosen (Co-founder) Rabbi Jeremy Rosen (Headmaster) Romney Coles (Chemistry) Dr. David Stamler (Headmaster) John Bunney (Physics) Ron Evans (Mathematics) Murray Roston (English & Hebrew) Ted Fields (Rowing) Malcolm Shifrin (Librarian) Dr. Alexander Tobias (Jewish Studies) Meir Gertner (Jewish Studies) Philip Skelker (Headmaster) Joe Dwek Deborah Dwek David Sheldon Jerrold Roston Jonathan Dwek   Feel free to leave a comment letting us know what you liked about this episode, and rate us on your favorite podcast platform

Carbohydrates: no longer just for your piehole. Stuff some knowledge into your ears with sugar scientist Dr. Michelle Dookwah and learn how your cells use carbs to communicate, what carbs have to do with your immune system, the whys behind your winter cravings, the hot goss on bread, and how much sugar you should really be eating. Also: Are all types of sugars sweet? You might be surprised by the answer!Follow Dr. Michelle Dookwah on InstagramFull-length (*not* G-rated) Glycobiology episode + tons of science linksMore kid-friendly Smologies episodes!Become a patron of Ologies for as little as a buck a monthOlogiesMerch.com has hats, shirts, hoodies, totes!Follow @Ologies on X and InstagramFollow @AlieWard on X and InstagramSound editing by Zeke Thomas Rodrigues & Jarrett Sleeper of MindJam Media, Steven Ray Morris, Jake Chaffee, and Mercedes Maitland of Maitland Audio ProductionsMade possible by work from Noel Dilworth, Susan Hale, Kelly R. Dwyer, Emily White, & Erin TalbertSmologies theme song by Harold Malcolm

Larry joins Angie to discuss the 200-page paper from the National Academy of Science published in 2012. This paper documents the incredible science of glycobiology. Larry breaks it down for us in easy-to-understand parts. This episode is part one! Tune in for this critical component of wellness. 

Professor Dr. Thomas Rademacher, MD, PhD, is CEO and Co-Founder of Emergex ( https://emergexvaccines.com/ ), a company that has developed a novel nanoparticle-based vaccine technology to deliver synthetic viral fragments via microneedles on a skin-adhesive patch. Emergex's approach works on the principle of priming immune T-cells, opening the door for the development of universal vaccines against highly mutagenic viruses such as the seasonal flu and covid. T-cell priming offers a superior inoculation strategy over traditional vaccines, which rely on the body's generation of antibodies and fail to keep up with seasonal mutations. A serial entrepreneur, Professor Rademacher also serves as Emeritus Professor of Molecular Medicine at University College London (UCL) and is widely considered one of the founders of biotech from the early 1980s (having been involved in many of it's core disciplines – from recombinant proteins, to monoclonal antibodies, to glycobiology). Professor Rademacher has authored over 200 publications and 50 patents – 19 of which are in the nanomedicine field. In addition to being a world leader in nanomedicine, he is also an expert in fetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia. Professor Rademacher was co-Founder of the field of Glycobiology and subsequent Glycobiology Institute in Oxford and co-founded Oxford GlycoSciences, the first of Oxford University's biotech spinouts, which, in 1998, was listed on the London Stock Exchange and reached a market capitalization of £1.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd. In 2000, Professor Rademacher entered into a collaboration with the Spanish Research Council and co-founded the first nanomedicine company, Midatech Ltd. Midatech floated on the AIM and NASDAQ stock exchanges in December 2015. Support the show

Join Dr. Kiltz and special guest Sami Tugano for a conversation on the transformative power of a metabolic approach to disease management and treatment.   Sami is a dedicated cancer consultant in Japan, specializing in metabolic approaches for cancer management. Sami's personal experience with stage 4 colorectal cancer that metastasized to her liver, lung, and lymph nodes has led her to adopt a unique approach to managing cancer. Sami has successfully kept her cancer at bay using a combination of the ketogenic diet, off-label drugs, and exercise. Sami remains committed to maintaining an active lifestyle, regularly hitting the gym for heavy lifting sessions, engaging in HIIT training, and enjoying running.   Now, Sami consults with clients who are seeking a comprehensive and true approach to cancer management. During consultations, Sami provides personalized guidance tailored to each individual's unique circumstances, aiming to enhance their body's metabolic flexibility and improve their quality of life.    In this episode you will discover:   Animal fat v.s. plant oils   Glycobiology   Why high fat matters   Low fat diet and disease   Learning from your apst to fuel your future     Connect with Sami:   Instagram  YouTube  Website    Connect more with Dr. Kiltz:  Website  Kiltz Mighty Tribe - Free membership and 30-Day Course   Doctor Kiltz Nutritional Solutions  Instagram  Tiktok  Facebook  Amazon 

In this episode, Xavier Bonilla has a dialogue with Ajit Varki about the evolutionary origins of denial and self-deception. They discuss the evolutionary perspective of human origins, self-awareness in humans, theory of mind, and how false beliefs and denial evolved. They also discuss lying, self-deception, religion, positive uses of deception, climate change, future of Mind Over Reality theory, and many more topics. Ajit Varki received training in physiology, medicine, biology, and biochemistry at the Christian Medical College, Vellore, The University of Nebraska, Omaha, and Washington University, St. Louis. He was trained and board-certified in internal medicine, hematology, and oncology. He joined the faculty of the University of California, San Diego (UCSD) in 1982.Dr. Varki is an elected member of the American Academy of Arts & Sciences, National Academy of Medicine, American Society for Clinical Investigation, Association of American Physicians, and of Sigma Xi. He has been a recipient of a MERIT award from the NIH, the American Cancer Society Faculty Research Award, as well as three of the highest honors in the field: the Karl Meyer Award (2005), the International Glycoconjugate Organization Award (2007), the Rosalind Kornfeld Award for Lifetime Achievement in Glycobiology (2020), and the ASBMB Herbert Tabor Research Award (2023). He was also elected President of the American Society for Clinical Investigation (1998–1999), President of the Society for Glycobiology (1996) and served Editor-In-Chief of the Journal of Clinical Investigation (1992–1997). He is  recognized for creating the first major open access research journal, The Journal of Clinical Investigation, JCI (1996), as well as the first major open access textbook, Essentials of Glycobiology (2008). Dr. Varki was honored with the Old Cottonian of Eminence Award at the 150th Anniversary of Bishop Cotton Boy's School in Bangalore, India (2015) and he was also honored with the Annual Research Day Distinguished Faculty Medal and Oration at his medical school alma mater, the Christian Medical College, Vellore, India (2020). Dr. Varki's interests in human evolution also led him to propose a novel Mind Over Reality Transition theory about human origins, in the book, Denial. Get full access to Converging Dialogues at convergingdialogues.substack.com/subscribe

TIME STAMPS: 00:08 Dr. Kiltz's credentials, accomplishments, and backstory. 02:40 The “BBEBIS” diet! 04:00 Dr. Kiltz's famous ICE CREAM recipe! It's a TREAT, not a CHEAT. 07:02 HIGHLY ADDICTIVE CHEMICALS found in most plants. 09:38 GLYCATION: the opposite of GLYCOSYLATION, like “rust” to our body, especially proteins. 12:02 Plants + lean protein = ALCOHOL in your GUT! 14:04 ADIPOSE TISSUE: Why it's the most nutritious part of the animal. 18:08 Occam's Razor: problem-solving principle that recommends searching for explanations constructed with the smallest possible set of elements. 23:03 The value of a COMMUNITY in your EXERCISE and in your FAITH! 30:40 PLANTS are the ULTIMATE PREDATORS. 39:00 SPIRITUAL & PHYSICAL FITNESS: Strength to overcome just about anything in this universe. 43:02 Dr. Kiltz's BOOKS & WRITING HABITS. 51:18 The misunderstood SCIENCE OF METABOLISM. Books referenced: Essentials of Glycobiology, Third Edition, by Ajit Varki & Introduction to Glycobiology by Maureen E. Taylor and Kurt Drickamer 57:01 INTRAMUSCULAR FAT and INSULIN INJECTIONS: Is this why so many bodybuilders are DYING YOUNG?

Could your steak dinner be tricking your immune system? In this episode we shed light on the connection between specific foods and colorectal cancer. Explore xeno-autoantigens, grasp the nuances of immunotherapy, and question the reliability of animal-derived heart valves. Vered Padler-Karavani is the principal investigator in the Department of Cell Research and Immunology at Tel Aviv University. Her research combines glycobiology, immunology, bio-nanotechnology, cancer research and xenotransplantation. Tune in to uncover the hidden connections between glycans, our diet, and the potential health repercussions.We discuss: Why study Glycobiology [01:35]Xeno-autoantigens & Xenosialitis [03:16]Where Does Neu5Gc Accumulate? [06:33]Red Meat & Colorectal Cancer [10:28]Tumor-associated Carbohydrate Antigens [11:54]Immunotherapy: Potential & Limitations [13:22]Animal-derived Heart Valves: Safety & Efficacy [20:02]Navigating Safety Regulations for Biologic Therapies [31:27] Neu5Gc in Foods: The Gcemic Index [34:14]Does Prof. Vered Padler-Karavani Still Eat Red Meat? [37:23]Neu5Gc as Biomarkers [38:08] Follow Vered on social media: LinkedInTwitter View the Show Notes Page for this Episode Engage with us on social media: Instagram LinkedInFacebookTwitter Please be advised that this show is for information only and should not be considered as a replacement or equal to medical advice. 

The longer lifespans we enjoy come shadowed by age-related diseases, notably Alzheimer's. This episode shines a light on the often-overlooked glycans, complex carbohydrates that play a pivotal role in healthy brain function. Our understanding of Alzheimer's causation has evolved, moving beyond just 'trash accumulation' to include problems with 'trash clearance.' Discover the potential of glycans in healing spinal cord injuries, the hurdles in identifying early biomarkers and delivering drugs to the brain. We delve into the essential role of gangliosides, a unique class of glycolipids, and separate science from media hype around Alzheimer's prevention. Ronald Schnaar is the Professor and Interim Director of the Department of Pharmacology and Molecular Sciences and a Professor of Neuroscience at Johns Hopkins University School of Medicine. Listen in as he unpacks his extensive research in neuro glycobiology and the practical hurdles in the path of Alzheimer's research and prevention.We Discuss:Why Study Glycobiology? What Drew Ronald to Glycobiology [02:41]Understanding the Crucial Role of Glycans in Cell-to-Cell Interaction [05:18]Study on Gangliosides in Context of Nerve Cell Insulation [06:29]Congenital Disorders of Ganglioside Biosynthesis: Symptoms and Treatment Options [12:03]The Potential Role of Glycans in Repairing Spinal Cord Injuries [18:17]The Evolution in Our Understanding of Alzheimer's Disease [20:45]Challenges of Studying Alzheimer's Disease [27:23]International Research Collaboration for Study of Alzheimer's Disease [31:09]Dual Causes of Alzheimer's: A New Perspective [32:37]Are Mice Good Models for Neurodegenerative Diseases? [34:42]The Challenge of Translating Research into Clinical Application [38:40]Challenges of Drug Delivery to the Brain [40:45]The Future of Glycan Biomarkers of Alzheimer's Disease [42:23]Alzheimer's Prevention: Sifting Fact from Fiction in Media Coverage [45:58]Ronald's Future Research Plans and Focus [51:27]Ronald's Final Message to Our Listeners [54:44]Follow Ronald on Social Media: LinkedInView the Show Notes Page for this EpisodeEngage with us on social media: Instagram LinkedInFacebookTwitter Please be advised that this show is for information only and should not be considered as a replacement or equal to medical advice. 

Larry joins Angie in this episode to discuss how the placebo effect works within the science of glycobiology. How do our mental thoughts influence our physical body? How does our thinking interact with feelings, hormones, individual cell receptors, and manifest change and healing within our bodies? The science of glycobiology has significant answers. 

It is a widely known fact that cardiovascular diseases are the leading cause of mortality and morbidity in both men and women, which puts an urgency on gaining a better understanding of them. One interesting lens to look at CVDs is through glycans. However, in order to do so, we need to uncover the answer to which came first, the chicken or the egg? Do glycans change in response to the disease? Or are they actively involved in disease development?  To figure this out, we welcomed Prof. Samia Mora to the podcast. Samia is a Professor of Medicine at Harvard Medical School and Director of the Centre for Lipid Metabolomics at the Brigham and Women's Hospital in Boston, Massachusetts. Her research focuses on risk factors and prevention of cardiovascular diseases (CVDs). Listen in as she introduces us to a number of modifiable risk factors and the cumulative effect both positive and negative behaviours have on future disease risk.  We Discuss:Introduction to Cardiovascular Diseases [01:15]The Key Role of Inflammation in Cardiovascular Disease Development [02:41]The 'Good vs Bad Cholesterol' Perspective: Is It Outdated? [04:05]Glycans: Their Role in Predicting Cardiovascular Disease Risk [08:09]A Look Back: What We Can Learn from the GlycA Biomarker from the 1980s [10:41]Unravelling the Impact of Obesity and Weight Loss on Cardiovascular Disease [15:03]The Glycan Dilemma: Do They Change in Response to Disease or Are They Partake in Disease Development? [21:47]Risk Factors for Cardiovascular Disease: Modifiable vs Non-Modifiable [25:55]Lifestyle Changes: A Proactive Approach to Prevention [31:38]The Effect of Weight Loss on Inflammation Levels [40:14]How Often Should Blood Lipid Levels Be Measured? [43:17]Glycans and Sex-Specific Cardiovascular Risk [48:18]Pregnancy and Menopause as Risk Factors for Cardiovascular Disease [50:02]Glycans: Effective Biomarkers of Cardiovascular Disease? [58:44] Follow Samia on social mediaTwitterView the Show Notes Page for This Episode Purchase a GlycanAge Test Engage with us on social media: Instagram LinkedInFacebookTwitter Please be advised that this show is for information only and should not be considered as a replacement or equal to medical advice.  

The concept of biological age might sound like a new notion, but it's something researchers have been looking at for 35 years. A person's biological age can tell us more about them than chronological age because it includes genetics, lifestyle and environmental factors. Since it's such an individualised metric, it's important to find a reliable way of measuring it. In the episode, Rina and her guest Dr Peter Joshi describe 11 different biological ageing clocks, the research behind them and why GlycanAge is such a great tool for providing not just an accurate measurement of your biological age, but also actionable tips you can incorporate to promote healthy ageing. Our guest is a Chief Scientist for Humanity Health, a company using digital biomarkers to measure and improve the rate of ageing.  We Discuss:How has our understanding of ageing changed [02:43]   What are the hallmarks of ageing [11:15]   Explaining the term biological age [14:25]    Multi-omics analysis of biological age [20:50]Are biological clocks predictive of chronological age [26:21]The benefit of measuring biological age [43:36]How to improve the biological clocks [46:45] Follow Peter on social mediaLinkedInHumanity Health View the Show Notes Page for This Episode Purchase a GlycanAge Test Engage with us on social media: Instagram LinkedInFacebookTwitter Please be advised that this show is for information only and should not be considered as a replacement or equal to medical advice. 

Glycans have a great capacity to fine-tune the inflammatory response and often determine how successfully the immune system distinguishes between friend and foe. While cancer cells build a glycan shield to hide from immune surveillance, pathogens can mimic our glycans in order to evade immune detection and perpetuate infection. Salomé Pinho is the Immunology, Cancer and GlycoMedicine Group leader at the Institute for Research and Innovation in Health at the University of Porto, her research focuses on cancer and inflammatory conditions. Listen in as she introduces us to the intricacies of immune regulation and the potential of glycans as diagnostic and prognostic biomarkers as well as immunotherapeutic targets. We Discuss: The role of glycans in immunological tolerance [4:51] Why has glycobiology been neglected for so long? [10:28]Cancer and immune tolerance [12:08] Glycans as cancer biomarkers and immunotherapeutic targets [20:00] Glycan mimicry in autoimmune diseases [23:48] Glycans as biomarkers of inflammatory bowel disease (IBD) [27:49] GlycanSwitch Project [35:33]  Follow Salomé on social media Facebook Twitter LinkedInView the Show Notes Page for This Episode Purchase a GlycanAge Test Engage with us on social media: Instagram LinkedInFacebookTwitter Please be advised that this show is for information only and should not be considered as a replacement or equal to medical advice. 

Sugars, also referred to as carbohydrates, aren't just substances we add to make coffee taste less bitter or food sweeter; they are an entire class of molecules necessary for life. The study of these carbohydrates is called glycobiology. Dr. John Hanover is a glycobiologist and the chief of the laboratory of cell and molecular biology at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). His work is advancing scientists' understanding of the sugar structures responsible for rare diseases and genetic transgenerational inheritance.

Have you ever heard of GlycoBiology? Larry Law is on the podcast to explain the science behind this latest research of GlycoBiology. After the Doctors told his wife there was nothing they could do for her, Both Larry and Angie went on a quest to improve his wife's health. Larry has studied GlycoBiology for years and has become an expert in his field. He and his wife started a non-profit organization called Angie's Option GRM (Grass Roots Movement) To help others be educated on this subject. With their organization, they have been able to help many around the world learn the study of Gycobiolgy and how this could be the missing puzzle in their health journey.

Have you ever heard of GycoBiology? Neither did Angie until her Doctor told her there was nothing they could do for her. Angie's body was dying, and she was running out of options. So she and her husband Larry went on a quest to find answers and stumbled upon a study called GycoBioligy. Angie and her husband started a non-profit organization called Angie's Option GRM (Grass Roots Movement) to help others learn about GioBiology. She has a fascinating story of how she got where she is today! Find more about Angie and Larry and their non-profit Angie's Option GRM at https://www.angiesoptiongrm.org/

Episode 16 of the Modern Chemistry podcast dives back into glycobiology and its practical application with Benjamin Schumann. Ben is a chemical biologist who studies the biology of carbohydrates (glycans). After completing his undergraduate biochemistry studies in Tübingen, Germany, he was trained in synthetic carbohydrate chemistry in the lab of Peter H. Seeberger at the Max Planck Institute of Colloids and Interfaces Potsdam and the FU Berlin. Developing vaccines against pathogenic bacteria based on synthetic glycans, Ben learned to apply his compounds in biological settings in vivo and in vitro. For his achievements, he received the Award for Excellence in Glycosciences and, in 2017, the prestigious Otto Hahn Medal by the Max Planck Society. During his postdoctoral work in the lab of Carolyn R. Bertozzi at Stanford University as an Alexander von Humboldt foundation Feodor Lynen fellow, Ben developed an interest in "precision tools" to study glycosylation of human cells in great detail. He started as a Group Leader at the Crick and Imperial College London in 2018.Towards the end of the show, Ben mentions a prize. Ben and colleagues from Imperial College and Stanford University were awarded the Royal Society of Chemistry's new Chemistry Biology Interface Division Horizon Prize, the Rita and John Cornforth Award. For more details, please check out this link on the Francis Crick Institute's website - https://www.crick.ac.uk/news/2021-06-08_research-prize-for-chemical-toolbox-to-study-the-role-of-cell-surface-sugars. You will hear the following terms used during the interview. I've included some descriptions here. Glycobiology - the study of complex sugar molecules in biological systems and cells.Glycobiome/glycoproteome – the total glycan make-up of a cell or organismGlycosylation – the addition of sugar molecules to other substances, often proteins.Glycans – complex sugar molecules composed of single sugar sub-units linked by chemical bondsChemical biology – the application of chemical techniques, and often small molecules produced by chemistry to study biological processes.Biochemistry – the study of biomolecules and pathways in living systemsLectins – highly specific carbohydrate-binding proteinsAntibody – a 'Y'-shaped protein produced by the immune system which identifies and binds to a specific substanceMonosaccharide – a single sugar subunitBioorthogonal chemistry – a chemical reaction that occurs in a living system without interfering with natural biochemistryGlycosyl transferase – enzymes which add a sugar (simple or complex) to an acceptor moleculeChemoenzymatic synthesis – producing chemical using biochemical pathways within cellsCRISPR - CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats, a family of specific DNA sequences in prokaryotes. Enzymes, such as 'Cas9' can modify DNA at these CRISPR sequences, editing in or out new DNA sequences. Although this technique is known correctly as CRISPR-Cas9, the discovery and development of a range of CRISPR-associated enzymes has led to the term 'CRISPR' being used as a generic term for this suite of gene editing technologies.Isoenzymes – enzymes that catalyse the same reaction, but have different amino acid sequencesProteolytic digest – breaking up a protein, or peptide, chain into smaller fragmentsFluorophore – a fluorescent molecule (in this case, used as a reporter molecule)Biotin tag – a chemical molecule used as a reporter for other biomoleculesBio-organic chemistry – scientific studies combining organic chemistry and biochemistry, which studies biological processes using chemical methods.

ReferencesKoning, Ruud & Matheson, Victor & Nathan, Anil & Pantano, James. (2014). The Long-Term Game: An Analysis of the Life Expectancy of National Football League Players. International Journal of Financial Studies. 2. 168-178. 10.3390/ijfs2010168. Fung TT, van Dam RM, Hankinson SE, et al. Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies.Ann Intern Med 2010, 153:289-298.Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.Novartis Found Symp 2004, 262:247-260; discussion 260-268.Salvioli S, Capri M, Bucci L, et al. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53.Cancer Immunol Immunother 2009, 58:1909-1917.Levine ME, Suarez JA, Brandhorst S, et al. Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population.Cell Metab 2014, 19:407-417.Vergnaud AC, Norat T, Romaguera D, et al. Meat consumption and prospective weight change in participants of the EPIC-PANACEA study.Am J Clin Nutr 2010, 92:398-407.Brewer GJ. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease.Exp Biol Med 2007, 232:323-335.Brewer GJ. Risks of copper and iron toxicity during aging in humans.Chem Res Toxicol 2010, 23:319-326.Padler-Karavani V, Yu H, Cao H, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease.Glycobiology 2008, 18:818-830.Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis.Nat Med 2013.Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.N Engl J Med 2013, 368:1575-1584.de Lorgeril M, Salen P. New insights into the health effects of dietary saturated and omega-6 and omega-3 polyunsaturated fatty acids.BMC Med 2012, 10:50.Lunn JC, Kuhnle G, Mai V, et al. The effect of haem in red and processed meat on the endogenous formation of N-nitroso compounds in the upper gastrointestinal tract.Carcinogenesis 2007, 28:685-690.Zheng W, Lee SA. Well-done meat intake, heterocyclic amine exposure, and cancer risk.Nutr Cancer 2009, 61:437-446.Lagiou P, Sandin S, Lof M, et al. Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study.BMJ 2012, 344:e4026.Lagiou P, Sandin S, Weiderpass E, et al. Low carbohydrate-high protein diet and mortality in a cohort of Swedish women.J Intern Med 2007, 261:366-374.Young VR, Pellett PL. Plant proteins in relation to human protein and amino acid nutrition.Am J Clin Nutr 1994,59:1203S-1212S.Rand WM, Pellett PL, Young VR. Meta-analysis of nitrogen balance studies for estimating protein requirements in healthy adults.Am J Clin Nutr 2003, 77:109-127.

Title: This week the Kaleidoscope team are talking about the unsung hero that is statistics, the maths that influences what we deem important in research, and an exciting emerging idea in schizophrenia. Citations: Gelman, A., & Vehtari, A. (2020). What are the most important statistical ideas of the past 50 years?. arXiv preprint arXiv:2012.00174 Mealer RG, Williams SE, Daly MJ et al. Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research. Molecular Psychiatry, 2020; 25:3129-3139.

In this episode, we're joined by a very special guest, Miruna! We talk about glycosylation (adding sugars to molecules) and its role in the microbiome, immunology and cancer. 

Carolyn Bertozzi grew up in a science family with a physicist father. But it was organic chemistry that “clicked” for Carolyn and started her down the path of understanding biology at a molecular level. Daniel Chen and Carolyn Bertozzi discuss her work in glycobiology. Bertozzi’s research finds that glycosylation has consequences in immune modulation, and that glycobiology plays an important role in human disease that has historically been underexploited in drug development. Finally, Chen and Bertozzi talk about gender representation in science and the importance of female role models for both women and men.

In this episode, we answer your questions! You asked us a variety of questions, including "are tongues ties on the rise?" and "what actually bursts in labour, and is it really water?" We also discuss advanced maternal age and induction of labour; and how to get enough clinical hours to become an IBCLC. There were so many questions this is only part one... Links:FROSTTIE trial https://www.npeu.ox.ac.uk/frosttie/cliniciansMills N, Pransky SM, Geddes DT, Mirjalili SA. What is a tongue tie? Defining the anatomy of the in‐situ lingual frenulum. Clinical Anatomy. 2019 Sep;32(6):749-61. https://onlinelibrary.wiley.com/doi/pdf/10.1002/ca.23343 Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012 Sep 1;22(9):1147-62. https://academic.oup.com/glycob/article/22/9/1147/1988076Bruce German https://www.ucdavis.edu/news/breast-milk-reveals-clues-health Dr. Rachel Reed https://rachel-reed.website/links/Books:Dr. Rachel Reed. Why Induction Matters. https://rachel-reed.website/books/

Recently glycans have been receiving a lot of attention. It turns out, the surface of coronavirus is packed with glycans, which help this virus evade our immune system.In this episode, we interviewed Dr. Parastoo Azadi, whose recent research sheds light on the structure of coronavirus core surface glycoprotein, and hence can facilitate the development of a vaccine against it.Together with Parastoo, we have discussed: ◦ Role of glycans in coronavirus infection ◦ Challenges in developing an effective vaccine against SARS-COV-2 ◦ Significance of glycobiology in the biotech industry ◦ Evolution of Mass Spectrometry ◦ NMR vs MassSpec in studying protein glycosylation ◦ Approaches to decipher glycan structures on the surface of proteins ◦ Role of glycan biomarkers in personalized medicine ◦ Improving antibody-based therapeutics with glycoengineering ◦ The future of glycobiologyGet in touch with Parastoo:Twitter: @CCRCUGALinkedIn: Parastoo AzadiWeb (Complex Carbohydrate Research Center):https://ast.uga.edu/Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

I'm not afraid of the gray area or the darkness that surrounds a few inches in front of your face, which is really what this business is all about." - Constantine Theodorpulos, Founder and CEO of Go Therapeutics

Carbohydrates: no longer just for your piehole. Stuff some knowledge into your ears with sugar scientist Michelle Dookwah and learn how your cells use carbs to communicate, the whys behind your winter cravings, the hot goss on the keto diet, and how much sugar you should really be eating. Also: B-movies about biology and the weirdest thing Alie ate today. Support the show.

Collectively rare disorders are more prevalent than cancer and many other commonly known diseases. It might seem obvious that something that is rare should warrant little of our attention. But science does not move in a straight line. A case could be made that exploratory, basic research might result in as much or more progress than research targeted only to the most common diseases. These choices must be made in the context of multiple stakeholders including healthcare professionals, scientists, funders of research, regulators, and patients. Hudson Freeze, Professor of Glycobiology & Director of the Human Genetics Program at Sanford Burnham Prebys Medical Discovery Institute explains the pervasiveness of rare disorders and the kinds of research being done. Series: "Exploring Ethics" [Health and Medicine] [Humanities] [Science] [Education] [Professional Medical Education] [Show ID: 31826]

Collectively rare disorders are more prevalent than cancer and many other commonly known diseases. It might seem obvious that something that is rare should warrant little of our attention. But science does not move in a straight line. A case could be made that exploratory, basic research might result in as much or more progress than research targeted only to the most common diseases. These choices must be made in the context of multiple stakeholders including healthcare professionals, scientists, funders of research, regulators, and patients. Hudson Freeze, Professor of Glycobiology & Director of the Human Genetics Program at Sanford Burnham Prebys Medical Discovery Institute explains the pervasiveness of rare disorders and the kinds of research being done. Series: "Exploring Ethics" [Health and Medicine] [Humanities] [Science] [Education] [Professional Medical Education] [Show ID: 31826]

Please click on the POD button to listen to the latest Atlanta Business Radio  show podcast broadcasting live each Wednesday at 10am EDT from Atlanta, GA, USA.   Atlanta Business Radio is sponsored by Fast Pitch! Networking - a one-stop shop for networking and marketing your business online and offline. Please go to their website www.fastpitchnetworking.com. When you sign up, please mention you were referred by Lee Kantor. That will help the show! Thanks. Here's how to listen to the podcast of our show. First click on the title of the show you are interested in. Then there should be a player in the upper right hand corner of the screen. Now just press play and the show you chose should start playing. You can also download the show to listen on your mp3 player. We are now available on iTunes, click this link and you can find all our past shows. Press SUBSCRIBE and you will automatically get the latest show when you sync your iPod to your computer.Remember if you want a pretty comprehensive listing of all kinds of Atlanta Events including Business Networking events please check out www.AtlantaEvent.com.  This morning Amy Otto couldn't make it and we had Nathan Hunt as our co-host and we talked all about Glycomics with Joseph McKenna. Joe is the host of a new radio show called Impact of Glycomics that can be heard worldwide every Wednesday at 11:00am EST. Joe explained that many researchers, physicians, and scientists believe that Glycomics may be the future of health. He said that more and more research institutes and universities around the world are discovering its importance. The Massachusetts Institute of Technology has declared the science of Glycobiology to be “possibly one of the ten greatest breakthroughs in the 21st century.? Part of the reason Joe created his radio show is that information about Glycomics, though readily available, is not mainstreamed in a way that encourages knowledge sharing. "Impact of Glycomics" is a radio show dedicated to that function. "Impact of Glycomics" is the lay person's and the professional's source for scientific knowledge. His shpow will bring together the great minds in this emerging field in order to share the depth of Glycomics while relating the information to the average citizen. The Impact of Glycomics show is created to bridge the gap between the scientists and the eventual end consumer, allowing for acquisition and understanding of research and the utilization of the new knowledge of the exciting goings on in the science of Glycomics. Please go Joe's website www.impactofglycomics.com for more information and to listen to the show every Wednesday at 11am EST. Also if you know of a business owner in Atlanta that we should know about please email Amy Otto at Amy @ atlantabusinessradio.com and we will try and get him or her on the show.

The olfactory system is a highly plastic region of the nervous system. Continuous remodeling of neuronal circuits in the olfactory bulb takes place throughout life as a result of constant turnover of primary sensory olfactory neurons in the periphery. Glycoconjugates are very important in olfactory development, regeneration and function. This article deals with different aspects of glycobiology relevant for the olfactory system. Various anatomical? developmental and functional subdivisions of the olfactory system have been labeled with exogenous lectins. The application of reverse lectin histochemistry resulted in the visualization of endogenous lectins, involved in fasciculation of olfactory axons. Numerous glycoproteins, among them members of the immunoglobulin superfamily, the cadherins and integrins as well as different,glycolipids and proteoglycans can act as surface adhesion molecules in the olfactory system. The olfactory-specific form of the sialoglycoprotein neural cell adhesion molecule is implicated in olfactory neuronal and axonal guidance. Glycoconjugates including laminin, fibronectin and proteoglycans are abundant components of the olfactory extracellular matrix, influencing neurite outgrowth and cellular migration. Immunohistochemical labeling has revealed occurrence of the carbohydrate differentiation antigen, playing a role in neurulation and morphogenesis of the very early olfactory system. The synaptic vesicle glycoprotein, appearing also early in olfactory development, is used as a marker of olfactory tumors. Finally, membrane and transmembrane glycoconjugates as well as secreted glycoconjugates may act as olfactory receptor molecules.